
Oncology NEWS International
- Oncology NEWS International Vol 17 No 4
- Volume 17
- Issue 4
Phase III trial of STS to prevent cisplatin-related hearing loss
Adherex Technologies Inc. has activated a phase III trial of sodium thiosulfate (STS) vs placebo to prevent hearing loss in children scheduled to receive cisplatin-based chemotherapy for newly diagnosed germ cell, liver, brain, nerve tissue, or bone cancers.
RESERACH TRIANGLE PARK, North Carolina-Adherex Technologies Inc. has activated a phase III trial of sodium thiosulfate (STS) vs placebo to prevent hearing loss in children scheduled to receive cisplatin-based chemotherapy for newly diagnosed germ cell, liver, brain, nerve tissue, or bone cancers. The trial, being conducted in collaboration with the Children’s Oncology Group, is expected to enroll up to 120 patients.
Articles in this issue
about 18 years ago
Proton therapy training offeredabout 18 years ago
Editor of Blood reviews a very bloody movieabout 18 years ago
Artists take note: Oncology on Canvas accepting entriesabout 18 years ago
PET affects treatment in over one-third of cancer casesabout 18 years ago
Expanded use of Axxent approvedabout 18 years ago
Gardasil supplemental application gets priority review designationabout 18 years ago
Optical tomo/US monitors adjuvant chemo responseabout 18 years ago
GIST patients resistant to imatinib/sunitinib respond to sorafenibabout 18 years ago
Sunitinib plus a taxane active in advanced breast cancerabout 18 years ago
Stanford V yields excellent outcomes in bulky, advanced HLNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content





















































